Targeting angiogenesis with monoclonal antibodies
نویسندگان
چکیده
منابع مشابه
Monoclonal antibodies targeting CD20
We are commenting on the article by Klein et al. on the functional properties of several anti-CD20 monoclonal antibodies (mAbs) in the January/February 2013 issue of mAbs. 1 Rituximab, the first monoclonal antibody approved for cancer therapy, has truly revolutionized the treatment of a variety of CD20 + hema-tological malignancies, 2,3 and also has been studied in a large number of autoimmune ...
متن کاملMonoclonal Antibodies
SUMMARY Monoclonal Antibodies are identical antibodies and Can be generated in ultimated amounts by countinuos cultures of single antibody- secreting cells. These cell lines are produced by cell fusion of normal lymphocytes to cells of a myeloma tumor cell line, which confers on the antibody producing hybrid cell, immortality and the ability grow as atumor in animals. monoclonal antibodies c...
متن کاملResponse to: Monoclonal antibodies targeting CD20
the standard rituximab regimen of 375 mg/mm2 based solely on a historical comparison of complete response (CR)/uncon-firmed CR rates from non-randomized Phase 1/2 clinical trials in (relapsed/refractory) follicular non-Hodgkin lymphoma (NHL) patients as it is stated in the letter of Goldenberg and colleagues. In line with this, the cited publications by Morschhauser et al. 5 and Negrea et al. 6...
متن کاملMonoclonal Antibodies Targeting LeLe-Related Glycans with Potent Antitumor Activity
Purpose: To produce antitumor monoclonal antibodies (mAbs) targeting glycans as they are aberrantly expressed in tumors and are coaccessory molecules for key survival pathways. Experimental Design: Two mAbs (FG88.2 and FG88.7) recognizing novel tumor-associated Lewis (Le) glycans were produced by immunizations with plasmamembrane lipid extracts of the COLO205 cell line. Results: Glycan array an...
متن کاملMonoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity.
PURPOSE To produce antitumor monoclonal antibodies (mAbs) targeting glycans as they are aberrantly expressed in tumors and are coaccessory molecules for key survival pathways. EXPERIMENTAL DESIGN Two mAbs (FG88.2 and FG88.7) recognizing novel tumor-associated Lewis (Le) glycans were produced by immunizations with plasma membrane lipid extracts of the COLO205 cell line. RESULTS Glycan array ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2006
ISSN: 0923-7534
DOI: 10.1093/annonc/mdl241